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Background: Inhaled allergen challenge is a standard method to study airway responses to inflammatory provocation
and evaluate the therapeutic potential of novel anti-inflammatory compounds in asthma. MEM 1414 is a novel oral PDE4
inhibitor with high affinity and selectivity creating the potential for an improved side effect profile vs non-selective PDE
inhibitors. We evaluated the tolerability and effect of MEM 1414 on airway responses in mild asthmatics.
Methods: A randomised double blind placebo controlled cross over study in two centres, in which sixteen steroid
naïve atopic asthmatics were challenged with inhaled allergen. Subjects were dosed with MEM 1414 (600 mg) or
placebo, twice daily orally for 7 days. Allergen challenge was performed on day 6 (2 hours post-dose), and
methacholine responsiveness was measured 24 hours post allergen (day 7). Biomarkers of drug effects using ex vivo
LPS stimulation of whole blood production of interleukin (IL)-6 and leukotriene (LT)-B4 and fractional exhaled nitric
oxide (FeNO) were measured on day 6 (0, 2 and 8 hours post-dose). Plasma pharmacokinetics were measured on
days 1, 6 and 7. The primary endpoint was the effect on late asthmatic response to allergen.
Results: Treatment with MEM 1414 abrogated the late phase response with a mean difference in FEV1 (LAR 3–10
hours) of 104 ml (25%) vs placebo (p < 0.005), with no effect on the early response. Biomarker responses were also
attenuated with MEM 1414 treatment with reductions in LPS-stimulated whole blood assays for TNFα at 8 hours
(p < 0.03) and LTB4 at 24 hours (p = 0.0808) with no change in the IL-6 response. The MEM 1414 treatment phase was
associated with higher incidence of nausea (6/16 MEM 1414 vs 2/16 placebo) and vomiting (3/16 vs 0/16 placebo).
Conclusions: Oral MEM 1414, a novel PDE4 inhibitor, significantly reduces the late response following inhaled allergen
challenge. MEM 1414 also inhibited whole blood assays of cytokine production from inflammatory cells. MEM 1414 was
associated with a typical adverse event profile of PDE4 inhibitors, namely nausea and vomiting although these were
mild side effects.
Trial registration number: Current controlled trials ISRCTN48047493.
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Although inhaled glucocorticoids are the mainstay of
current asthma therapy there remains a considerable
group of patients with poor symptom control [1] which
has led to the search for novel anti-inflammatory therap-
ies. The non-selective oral phosphodiesterase (PDE) in-
hibitor theophylline has been used as a treatment for
asthma for many years. However, it has a low therapeutic* Correspondence: brian.leaker@qasmc.com
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unless otherwise stated.index due to limited potency and a poor side effect profile
[2,3]. Selective PDE4 inhibitors have recently been devel-
oped with the aim of improving the therapeutic index, as
the PDE4 isoform is highly expressed on inflammatory
cells involved in asthma and COPD, such as mast cells, eo-
sinophils, T lymphocytes, macrophages and neutrophils
[4,5]. PDE4 inhibition reduces breakdown of cyclic 3’5’-
adenosine monophosphate (cAMP) and increases phosphor-
ylation of intracellular proteins, resulting in in vivo effects
including smooth muscle relaxation and suppression of
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effective in reducing allergen induced inflammation
[7,8]. Clinical studies have also shown efficacy for other
orally administered PDE4 selective inhibitors on relevant
asthma endpoints such as inhibition of allergen chal-
lenge [9,10] and exercise induced bronchoconstriction
[11], as well as improvements in lung function [12].
However, the tolerability of these orally administered
drugs is limited by side effects such as gastro-intestinal
symptoms [13-15].
MEM 1414 was screened with a standard panel of over
75 binding sites for receptors and ion channels, and 30
enzymes. MEM 1414 was found to be highly selective
for the PDE4 binding site and selectively inhibited PDE4
enzyme activity. MEM 1414 has nanomolar affinity, and
high selectivity for PDE4 over other PDEs such as 1, 2,
3, 5, 6 and 7, and shows efficacy in animal models of
pulmonary inflammation (data on file, Memory Pharma-
ceuticals Corp.). In human recombinant enzyme inhib-
ition assays the IC50 values for MEM 1414 on PDE4A,
PDE4B and PDE4D were 22 nM, 18 nM and 12 nM re-
spectively, demonstrating that MEM 1414 is a non-
selective PDE4 inhibitor. These values are similar to and
comparable with the non-selective PDE4 inhibitor roflu-
milast which display IC50 values of 0.9, 0.2 and 0.4 nM
for PDE4A, PDE4B and PDE4D respectively [16]. In vivo
data from rat models found MEM 1414 at 30 and
100 mg/kg orally inhibited LPS-stimulated neutrophil
lung infiltration. MEM 1414, at 30 and 100 mg/kg, re-
duced the number of eosinophils in rat lung 48 hours
after exposure to ovalbumin. LPS-stimulated TNFα pro-
duction in whole blood was inhibited by doses of MEM
1414 from 0.1 to 100 mg/kg in rats. A dose of 30 mg/kg
MEM 1414 i.p. significantly increased cAMP levels in
rat hippocampus, consistent with its proposed method
of action. These pre-clinical data suggest that MEM
1414 may be an effective and selective PDE4 inhibitor with
a potent anti-inflammatory effect. The aim of this proof of
concept study was to investigate the effects of MEM 1414
on allergen-induced responses in subjects with mild asthma.
Methods
Subjects
Sixteen steroid naïve subjects with a confirmed diagnosis
of asthma for at least 6 months were recruited. Subjects
were aged between 18 to 55 years and non-smokers. At
screening, subjects were required to have a forced expira-
tory volume in 1 second (FEV1) >75% predicted, have a
positive skin test to either house dust mite, grass pollen or
cat allergen, and to demonstrate both an early and late
asthmatic reaction to one of these allergens when inhaled.
All subjects provided written informed consent. The study
was approved by London Research Ethics Committee
(now called Brent REC); reference number 08/H0718/73.Study design
This was a two centre double-blind, randomised, placebo
controlled, cross-over study. Eligible subjects were ran-
domised to receive MEM 1414 600 mg orally once daily
(6x100 mg tablets) for 7 days (Figure 1). The washout
period was 2–10 weeks between treatment periods. Dos-
ing was performed under supervision at the sites on day
1, 6 and 7. On days 2–6 subjects were instructed to take
the study medication at the same time of day, and were
required to complete a diary card to document the time
that medication was taken. Heart rate, blood pressure,
ECGs, FEV1 and fractional exhaled nitric oxide (FeNO)
were measured pre-dose and at 1 hour post-dose on
days 1, 6 and 7. On day 6, an inhaled allergen challenge
was subsequently performed after the 1 hour post-dose
FEV1 and FeNO measurements. Methacholine challenge
was then performed at 24 hours post allergen challenge.
Adverse events and beta agonist use were monitored
throughout the study with the aid of diary cards. A
6 day treatment period was considered sufficient to
allow MEM 1414 to achieve steady state plasma concen-
trations. A minimum washout period of 2 weeks was
specified after the first treatment period to allow allergic
inflammation induced by allergen challenge to return to
normal in these subjects. It also allowed adequate time
to ensure that all active drug had been eliminated from
the body and its effects had vanished before the follow-
ing treatment period. For subject eligibility, FEV1 taken
on day 1 of the first treatment period had to be within
15% of mean screen FEV1 (baseline). The day 1 FEV1 of
treatment period 2 must also be within 15% of the FEV1
achieved on day 1 treatment period 1, if it was outside
15%, the subject was allowed to repeat the second treat-
ment period day 1 visit within 10 weeks or was consid-
ered a withdrawal.Dose selection
Pre-clinical toxicology studies in rat and dog determined
the NOAEL was 250 and 300 mg/kg/day respectively for
both species. These oral doses produced plasma levels of
73 μg · hr/mL in rat and 116 μg · hr/mL in dogs. These
studies were used to underwrite the selection of dose for
clinical studies. Calculations using allometric scaling
models suggested that the equivalent dose in humans
would be 600 mg MEM 1414 with projected AUC 95 μg ·
hr/mL after 1 week dosing (data on file, Memory Pharma-
ceutical Corp.). In humans MEM 1414 has been studied in
5 clinical trials, in single ascending dose studies ranging
from 15 mg to 1000 mg and in a 14 day multiple ascend-
ing dose trial ranging from 50 mg to 400 mg. Plasma con-
centration of MEM 1414 increased in a dose proportional
manner. Adverse event data suggest MEM 1414 was well
tolerated and no emesis reported.
Mild Asthma, 18 -55 years
Eligibility Criteria
Methacholine Challenge at S1
Allergen challenge at S2
Eligibility Criteria confirmed





Treatment Period A (7 days)
Allergen challenge at A6
Methacholine challenge at A7
PK sampling at A6 and A7




Visit  A6, Visit A7
1:1
Post Allergen Challenge Wash-out 1 (14-70 days)
Metacholine challenge
PK samplingVisit B1 
MEM1414
Treatment Cross-Over
Treatment Period B (7 days)
Allergen challenge at B6
Methacholine challenge at B7
PK sampling at B6 and B7




Visit B6, Visit B7
1:1
Post Allergen Challenge Wash-out 2 (14-70 days)
Follow-UpFUP Visit  FUP assessments 5-10 days post last dose of 
study drug.
Figure 1 Flow chart showing study design. FeNO denotes exhaled nitric oxide. Allergen = inhaled allergen challenge. Methacholine = inhaled
methacholine challenge.
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Bronchial challenges were performed as we have previ-
ously described [17,18] using a Mefar Dosimeter (Mefar,
Bologna, Italy). Subjects were assessed for sensitivity to
house dust mite, cat, grass pollen, and positive and nega-
tive controls by skin prick tests (Soluprick SQ, Alk Abelló
(Reading, UK). The allergen for inhalation was selected ac-
cording to the largest skin test wheal (positive >3 mm)
and clinical history. Fresh solutions of allergen were made
up in 0.9% saline in doubling concentrations from 250
SQ-U/ml to 32 000 SQ-U/ml. At screening, incremental
doses of allergen were inhaled [17] until an early asthmatic
response (EAR) was observed, defined as a fall in FEV1
of ≥20% from the post saline value, on at least one occa-
sion, between 5 and 30 minutes after the final concentra-
tion of allergen. The late asthmatic response (LAR) was
defined as a fall in FEV1 of ≥15% from the post saline
value, on at least three occasions, two of which must be
consecutive, between 4 and 10 hours after the final con-
centration of allergen. During the treatment periods, the
total dose of allergen required to cause an EAR and LAR
was administered as a single bolus dose. Subjects were ad-
ministered doubling concentrations of methacholine from
0.03125 to 32 mg/ml until a ≥20% fall in FEV1 was
achieved or the highest concentration of methacholine
was administered. The provocative concentration requiredto reduce the FEV1 by 20% of the post-saline baseline
value (PC20) was derived by linear interpolation between
the lowest concentration that caused a >20% fall and the
preceding concentration, as described [17].
FeNO
Standardised FeNO measurements were performed using
the NIOX® (Aerocrine, Solna, Sweden) with 3 valid tests
being done to ensure reproducibility.
Ex-vivo LPS/A23187 challenge
For each subject, a 5-point (including a vehicle control)
MEM 1414 dose–response curve was constructed during
the baseline assessment. This allowed a calculation of
the percentage of inhibition of cytokine production for
each specific subject during the treatment phase. Whole
blood was diluted with supplemented RPMI and incu-
bated with 4 concentrations of MEM 1414 and a vehicle
control for 30 minutes at 37°C/5% CO2. Cells were then
stimulated with increasing concentrations of either LPS
(for subsequent TNFα, IL-6 measurement) or calcium
ionophore A23187 (LTB4). Blood was processed as fol-
lows: blood was collected at each treatment period at
the following times: post-dose/pre-allergen challenge
and 3 and 8 hours post allergen challenge on day 6 and
at 24 hours post-dose/post-challenge on day 7 for the
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LTB4. Whole blood was drawn into lithium-heparinized
tubes, then transferred to plastic tubes containing hep-
arin (50 U/ml) and kept at room temperature for a
period no greater than 2 hours. Whole blood (200 μl)
was pipetted into 96 well plates with 10 μl of either LPS
(0.001 – 10 μM) or A23187 (0.1 – 20 μM) which were
placed into a 37°C incubator in an atmosphere of 5%
CO2 in air for 18 hours. Plates were then centrifuged
(250x g for 10 minutes) and aliquots of plasma frozen
(20°C) for assessment of cytokine responses. TNFα and
IL-6 were measured by Luminex xMAP platform and
commercially available assay kits from R & D systems
(Abingdon, UK). LTB4 was analysed using stand-alone
ELISA kit supplied by Assay Designs Inc (Exeter, UK).
Pharmacokinetic sampling and bioanalytical method
On day 1 blood samples were collected pre-dose, and 1,
2 hours post-dose, and on day 6 pre-dose, and 0.5, 1, 1.5,
2, 4, 8, 12 hours post-dose, and on day 7 pre-dose. Plasma
concentrations were analysed by liquid chromatography-
tandem mass spectrometry.
Statistics
Minimum LAR was derived as the minimum FEV1 value
over 4–10 hours post-allergen challenge. Minimum EAR
was derived as the minimum FEV1 over 0–2 hours post-
allergen challenge. Weighted mean LAR and EAR end-
points were derived by calculating the AUC over the
relevant time interval using the linear trapezoidal rule
and dividing by the time interval. Twelve evaluable sub-
jects were considered to sufficient to detect a difference
of 50% in the LAR (area under the curve from 3–10
hours, AUC 3–10 h) between MEM 1414 and placebo
with 80% power, assuming a within subject standard de-
viation of 50% and a 2-sided alpha significance level of
0.05 in a cross-over design. In order to achieve this, ap-
proximately 16 subjects were to be randomized to
achieve a minimum of 12 evaluable subjects. The pri-
mary efficacy parameter is the LAR as defined by the
area under the curve from 3–10 hours (AUC 3–10 h).
This was calculated from the change in the observed
FEV1 (L) compared to baseline (highest of pre-allergen
challenge values) using the trapezoidal method. The
EAR as defined by AUC 0–3 h was analysed in the same
way as the LAR. Comparison between treatments for
FEV1 AUC 3–10 h were carried out using an analysis of
variance for a cross-over design (ANOVA) with centre,
subject (sequence and subject within sequence), period
and treatment as factors of the model. Statistical analysis
was performed on the log 2-transformed values of the
provocative concentration of methacholine required to
produce a 20% reduction in FEV1 (PC20) to compare
MEM 1414 with placebo. A mixed effects model wasfitted with the factors treatment and period treated as
fixed effects and subject as a random effect.
FeNO change from baseline ratio at all time points were
analysed following a loge-transformation to compare MEM
1414 with placebo. A mixed effects model was fitted with
the fixed effects period, treatment group, subject-level loge-
transformed baseline, period-level loge-transformed base-
line, planned relative time, treatment group by planned
relative time interaction term and period-level loge-
transformed baseline by planned relative time interaction
term and the random effect subject.
Ex-vivo LPS challenge baseline assessments were com-
pared by ANOVA followed by Dunnetts multiple compari-
son test. The concentration response data from treatment
periods were plotted for each subject at each time point
and the effective concentration to give the 95% maximal re-
sponse (ECmax) was derived from a sigmoidal regression
was fitted to this data using the variable-slope four-
parameter logistic dose–response model for each of the cy-
tokines. MEM 1414 and placebo were compared by
ANOVA on the ECmax change from pre-challenge.
Pharmacokinetic parameters were estimated using
non-compartmental methods. Samples obtained from
placebo subjects were all below limits of quantification.
Results
Forty-seven subjects were screened and 16 suitable subjects
identified who were randomized and completed the study;
with 8 at each site. The mean age was 33 ± 7 years with a
male:female ratio of 6:10. Mean BMI was 25 ± 4. Mean
highest FEV1 and predicted were 3.2 ± 0.57 L and 94.89 ±
12.46% respectively. Mean FeNO was 61.82 ± 44.62.
Allergen challenge
Each subject received the same allergen throughout the
study, selected based on history and skin prick reaction
to house dust mite (n = 10), grass pollen (n = 4) and cat
(n = 2).
There was no significant period or sequence effect.
Treatment with MEM 1414 abrogated the late phase
response with a mean difference in FEV1 AUC (3-10 h)
of 104 ml; this was a 25% reduction compared to placebo
(p < 0.005), with no effect on the early response (Figures 2,
and 3). The total asthmatic response as defined by FEV1
AUC 0-10 h also showed a significant difference between
treatments (p = 0.0066).
Methacholine PC20
The analysis used only the 11 subjects with complete data
and the effect of treatment did not reach statistical signifi-
cance. There was no significant period or sequence effect.
The fold difference between the change in MEM 1414 and
placebo from day 7 to day 1 was 1.34 mg/mL ±1.52 (geo-
metric mean ± S.D., p = 0.38).
Figure 2 Mean FEV1 over time. Early and late asthmatic response to inhaled allergen challenge after 6 days treatment with either MEM 1414 or
placebo. Means and 95% confidence intervals, change in FEV1 compared to post saline value shown.
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The change from day 1 to day 6 post-dose/pre-challenge,
and on day 6 at 8 hours post-challenge and day 7 at
24 hours post-challenge are shown in Figure 4. There
were no differences between MEM 1414 and placebo.
There were no significant period or sequence effects at
any timepoints.
Ex-vivo LPS/A23187 challenge
The baseline TNFα release from subjects is shown in
Figure 5A. TNFα release was stimulated by the addition
of 1 μM LPS. Data from IL-6 and LTB4 are not shown.
A summary of the changes from pre- to post-allergen
challenge are shown in Figure 5B for TNFα post dosing.* 
Figure 3 Primary and secondary efficacy parameters. Box whisker plot
maximum and minimum values.At 8 hours post-allergen challenge there was a signifi-
cant difference between MEM 1414 and placebo for the
change in TNFα response from baseline (p < 0.038).
There were no significant treatment effects seen in IL-6
(data not shown). In the LTB4 data at 24 hours post aller-
gen challenge there was a trend to a difference between
MEM 1414 and placebo change from baseline, however
this was not significant (p = 0.0808;data not shown).
Pharmacokinetics (PK)
Plasma concentrations of MEM 1414 were available in a
total of 16 subjects. PK analysis of data following dose ad-
ministration on day 6 is shown in Table 1. Plasma concen-
trations of MEM 1414 on day 1 and day 6 showed a Tmax** ***  
showing median, upper and lower quartiles. Whiskers represent the
Figure 4 Exhaled nitric oxide. Box whisker plot showing median, upper and lower quartiles. Whiskers represent the maximum and minimum values.
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17000 ng/ml ±8500 with no evidence of accumulation
using the 2 hour time point to compare the ratios at 1 and
2 hours on days 1 and 6 (ratio 1.0, at 1 h and 1.1, 2).
Adverse events (AEs)
Overall 14 subjects (87.5%) reported at least one AE in
either the MEM 1414 or placebo treatment periods.
More subjects reported AEs during treatment with
MEM 1414 compared to during treatment with placebo
(81.3% versus 56.3%), primarily due to a higher incidence
of nausea, headache and diarrhoea during MEM 1414
treatment (Table 2). No subjects had an AE considered
severe, no subjects were withdrawn due to an AE and
no severe AEs were reported. The most common system
organ classes with subjects reporting AEs were gastro-
intestinal disorders (10 subjects, 62.5%) and nervous sys-
tem disorders (9 subjects, 56.3%). The majority of the
AEs were mild (8 subjects [50.0%] reporting mild events
only and 5 subjects [31.3%] reporting moderate events
in the MEM 1414 treatment period and 5 subjects
[31.3%] reporting mild events only and 4 subjects
[25.0%] reporting moderate events in the placebo treat-
ment period).
Gastrointestinal AEs were reported in a higher number
of subjects following MEM 1414 treatment compared to
placebo, with most of these events being considered
drug-related by the investigators. There were no changes
in any mean laboratory values over time.Discussion
This was a proof-of-concept study to determine the ef-
fect of MEM 1414 on allergen induced responses in mild
asthmatics. There was a significant attenuation of the
LAR in subjects treated with MEM 1414 which met the
primary end-point of the study and this attenuation of
the LAR is comparable in magnitude of effect to other
oral and inhaled anti-inflammatory agents [9,10,17,18].
For example oral roflumilast (IC50 0.5 nM average for
PDE4-A, −B and -D) and reduction in LAR AUC of 43%
[10,16] and inhaled inhibitors GSK256066 IC50 0.0032
nM and a reduction in LAR of 34% [18,19] and
CHF6001 IC50 0.026 nM with corresponding fall in LAR
of 30% [20].
The allergen-induced response is a robust model that is
commonly used to assess the therapeutic potential of novel
treatments for asthma [9,10,17,18,21-26]. All of the cur-
rently available and effective treatments for asthma modify
the LAR following allergen-induced responses and there
are no false positives [27]. These medications include
short-acting and long-acting inhaled β2-agonists, inhaled
corticosteroids, cromones, methylxanthines, leukotriene
inhibitors, and anti-IgE monoclonal antibody. Comparing
the results of different allergen challenge studies requires
caution, as methodological details such as the period of
measurement of the late response can vary between stud-
ies (we measured up to 10 hours while some studies only
measure up to 7 hours), and individual patient characteris-
tics may differ. The magnitude of attenuation of the LAR














































Figure 5 TNFα release in stimulated whole blood. (A) MEM 1414
concentration response curve baseline assessment for TNFα release
in whole blood. Blood was stimulated with 1 μM LPS. *p < 0.05
ANOVA. (B) TNFα release in whole blood during treatment periods.
Data shows change in ECmax TNFα release from pre allergen
challenge compared to 3, 8 and 24 hours post allergen challenge.
*p = 0.038 ANOVA. Data are mean ± S.D. AC: allergen challenge.
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the orally administered PDE4 inhibitor roflumilast, which
inhibited the maximal fall in the EAR and LAR by 14-28%
and 16-43% respectively [10,28]. The level of inhibition of
the LAR AUC of 25% seen in our study is similar to the
results with an inhaled selective PDE4 with identical
methodology [18] and greater than seen with IL-4 muteinTable 1 Summary statistics of PK analysis (ITT population)
N = 16 Cmax (ng/mL) Tmax (h) AUCt (ng.h/mL) A
Mean 17000 1.9 87600 8
SD 8500 1.2 47300 4
Min 5530 0.9 26000 2
Median 17600 1.7 84700 8
Max 34300 4.6 201000 2
GM 14800 1.6 75800 7
CV% 50.0 63.2 54.0 5pitrakinra (6% difference from placebo) by blocking the
common receptor to IL-4 and IL-13 [22]. The lack of ef-
fect on the EAR may indicate that MEM 1414 has less ef-
fect on mast cell degranulation as seen with inhaled
corticosteroids [21,23,24]. Previous studies with inhaled
PDE4 inhibitors have shown mixed results on EAR, cer-
tain studies show an inhibition of EAR [10,18,28], while
other studies show no effect on EAR [9,19].
Following allergen challenge, mast cell activation is pro-
longed and leads to a more complex immune response –
the LAR in certain selected asthma subjects [29]. The
LAR involves T cell activation, influx of eosinophils and
other inflammatory cells, with the release of cytokines and
other inflammatory markers. Group 2 innate lymphoid
cells (ILC2) are also important in the innate immune re-
sponse by releasing large amounts of IL-13 and IL-5 in re-
sponse to IL-33 from endothelial cells, and ILC2 cells play
a role in the type 2 polarisation of T cells [30,31]. PDE4 is
expressed on cells involved in both innate immune re-
sponse (mast cells) and the Th2 type inflammatory re-
sponses (eosinophils, macrophages and lymphocytes)
[5,26,32]. PDE4 is also expressed on smooth muscle cells
and has been shown to be involved in NANC neuronal in-
flammation in both guinea pig and human bronchus
[33-35]. PDE4 inhibits both the inflammatory mechanisms
and inhibits the regulatory networks that inhibit allergen
responses. The LAR is therefore a well validated model to
study inhibition of allergic inflammation, which supports
the prediction of clinical efficacy.
The secondary endpoint measurements of methacho-
line challenge post allergen, or exhaled NO were un-
changed by treatment. The study was not powered to
show a difference in the secondary parameters and only
11 sets of paired data were obtained for methacholine
challenge. This observation is often made in such studies
as subjects lung function remain hyper-responsive post-
allergen challenge and further procedures performed
after this procedure such as methacholine challenge
often cannot be performed for safety reasons.
Studies using inhaled corticosteroids have shown both
attenuation [21,25,26] and no attenuation [36] of metha-
choline reactivity post allergen challenge. In line withUC0-24 (ng.h/mL) AUC (ng.h/mL) λz (1/h) t1/2 (h)
7600 89000 0.1313 6.8
7300 33800 0.0995 2.5
6000 41300 0.0740 1.8
4700 85700 0.0881 7.9
01000 151000 0.3849 9.4
5800 83500 0.1120 6.2
4.0 38.0 75.8 36.8
Table 2 Summary of AEs reported in more than one
subject (safety population)
MEM 1414 Placebo
N = 16 (%) N = 16 (%)
Subjects who reported any AEs 13 (81.3) 9 (56.3)
Nausea 7 (43.8) 2 (12.5)
Headache 6 (37.5) 2 (12.5)
Diarrhoea 4 (25.0) 0
Vomiting 3 (18.8) 0
Dizziness 3 (18.8) 1 (6.3)
Chest discomfort 2 (12.5) 2 (12.5)
Dysgeusia 1 (6.3) 2 (12.5)
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to have no effect on methacholine reactivity post aller-
gen challenge in one study [21] but an inhibitory effect
in another [17]. These variable results suggest that
methacholine reactivity post-allergen challenge is not a
robust primary endpoint to evaluate drug effects.
Reducing FeNO levels by specific iNOS inhibition does
not inhibit the EAR or LAR, suggesting that nitric oxide
is not mechanistically involved in the pathophysiology of
allergen-induced asthma [17]. However, FeNO is a sensi-
tive biomarker and practical surrogate marker to moni-
tor inhaled corticosteroid therapy [37-39]. Raised levels
of FeNO are associated with inflammation in asthma
and are sensitive to suppression by steroids and also as-
sociated with levels of asthma severity [40,41]. The
effects of the leukotriene receptor antagonist montelu-
kast are more variable, with no inhibition observed of
nitric oxide observed in some studies [17,42]. The use-
fulness of FeNO as a biomarker appears to vary with the
class of drug, and our results and others [18] suggest
that airway nitric oxide production is a PDE4 independ-
ent mechanism. Alternative explanations are that the
current study was too short or underpowered to detect a
reduction in exhaled nitric oxide. Inhibition of TNFα re-
lease by PDE4 inhibition has been shown in vivo from
monocytes, tracheal smooth muscle and recruitment of
eosinophils to the airways following antigen challenge in
immunized guinea-pigs and rabbits [43]. Roflumilast dis-
played a modest inhibition of LPS-induced TNFα release
in subjects after 4 weeks treatment. TNFα release was
inhibited by 1.3 fold in monocytes ex vivo [11]. Murine
studies have shown that PDE4B is the main isoform for
mediating the release of TNFα in response to LPS as
well as other Th2 cytokines and eosinophil recruitment
[44-46]. Monocytes, neutrophils, eosinophils and T lym-
phocytes almost exclusively express PDE4 and not any
other PDE isoform [47,48]. The effects of PDE4 on cellu-
lar function usually involve isolation and purification of
the cell under investigation [49] or are performed inwhole blood [43]. Inhibition of TNFα release from whole
blood is consistent with findings observed with isolated
cells, and further supports the mechanism of action of
an anti-inflammatory effect for this class of agents [43].
Animal studies have suggested the potential benefit in
the use of non-selective PDE4 inhibitors for targeting in-
flammatory cells compared with selective inhibitors of
PDE4 isoforms. Recruitment of eosinophils in airway in-
flammation is no different in mice deficient in PDE4D
than in wild type control mice, however in the PDE4
knock out mice, methacholine induced airway obstruction
was eliminated [50]. This indicates that other PDE4 sub-
types are involved in the metabolism of cAMP. PDE4B
knock out mice do not undergo typical allergic inflamma-
tion responses such as Th2 cytokine production, eosino-
phil recruitment and bronchial hyperresponsiveness [45].
These two studies, amongst others, suggest a complemen-
tary role of PD4 isoforms in allergic airway inflammation
and the need to target several PDE4 isoforms, especially as
the inflammatory response is inhibited by non-selective
PDE4 inhibitors such as rolipram and roflumilast [51].
There were few adverse effects in this study, but the in-
cidence of gastro-intestinal side effects is comparable to
that associated with other oral PDE4 inhibitors [13-15].
The pharmacokinetic analysis performed showed a Cmax
concentration of MEM 1414 at 1–2 hours post-dose was
17,000 ng/ml (40 μM).These plasma concentrations are
much greater than the mean Cmax of roflumilast adminis-
tered orally (2,000 pg/ml) with good tolerability (although
lower than the active metabolite roflumilast N-xide) [52]
yet the in vitro IC50 values were similarly potent, with Ki
values on purified human recombinant PDE4 isozymes (Ki
22, 18 and 12nM for the PDE4A, PDE4B and PDE4D iso-
zymes; data on file, Memory Pharmaceuticals Corp.). Simi-
lar studies with V11294, and apremilast also showed
good tolerability but also had lower concentrations (2–
4000 ng/ml) [43,49] In our study plasma concentra-
tions at Cmax were approximately ten fold higher than
in studies with other PDE4 inhibitors and an absence
of GI side effects [43,49]. The selection of the dose for
this study was empirical based on the maximum toler-
ated dose from previous studies in human volunteers
and selected to ensure adequate PDE4 inhibition. The
maximum tolerated dose is often selected for allergen
challenge studies to increase the likelihood of success.
Dose response studies are not commonly performed
using the preferred cross over design in this type of
study. It is often the case that doses selected for the
first proof of concept study are too high and not neces-
sarily relevant for subsequent clinical studies. Altering
the pharmacokinetic properties of the formulation of
MEM 1414 to avoid such high Cmax concentrations of
MEM 1414 may be a promising way to improve the
side effect profile.
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maximal LPS concentrations <16 ng/ml with both MEM
1414 and V11294 [43]. However TNFα inhibition in the
present study was delayed to the 8 hour time point and
not seen at tmax with concentrations when peak MEM
1414 concentrations were well in excess of the EC50 ex-
vivo (40 μM; 3x greater than EC50). A delay in equilibra-
tion to an active compartment may explain this delay in
ex-vivo pharmacodynamics effect (Figure 5).
Oral PDE4 inhibitors have also been reported to show
clinical efficacy in COPD patients [13-15], but with a sig-
nificant rate of side effects. The information on the inci-
dence of GI side effects for PDE4 inhibitors in asthma is
less known. Although the current study using MEM 1414
was focused on asthma, using this drug in COPD would
also be of interest.
Conclusions
Oral MEM 1414 is a novel PDE4 inhibitor with nano-
molar potency and high selectivity over other PDE iso-
forms. Treatment with MEM 1414 significantly reduces
the late response following inhaled allergen challenge.
MEM 1414 also inhibited whole blood assays of cytokine
production from inflammatory cells. MEM 1414 was as-
sociated with a typical adverse event profile of PDE4 in-
hibitors, namely nausea and vomiting although these
were mild side effects. Further development of MEM
1414 in inflammatory lung disorders such as asthma or
COPD would be warranted given that a successful aller-
gen challenge study has a useful predictive value in sub-
sequent studies of clinical efficacy.Abbreviations
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